Clinical Trial: The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia

U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06849401) titled 'The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia' on Feb. 21.

Brief Summary: To learn if the VGO-Cs01p can help to control CD7-positive relapsed/refractory acute T-lymphoblastic leukemia (R/R T-ALL) in children.

Study Start Date: Feb., 2025

Study Type: INTERVENTIONAL

Condition: T-ALL

Intervention: BIOLOGICAL: VGO-Cs01p

Off-the-shelf NK cell products derived from human embryonic stem cells (hESCs)

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Shanghai Jiao Tong University School of Medicine

Information provided by (Responsible Party): Hui Zhang, Shanghai...